WNBA Star Sentenced to 9 Years for Marijuana Possession in Russia

Dec.09.2022
WNBA Star Sentenced to 9 Years for Marijuana Possession in Russia
WNBA star Brittney Griner sentenced to nine years in Russian prison for possession of marijuana in her luggage.

According to Russian authorities, WNBA star Brittney Griner was found with a marijuana electronic pod in her carry-on luggage at a Moscow airport in February of this year. As a result, she has been sentenced to nine years in a Russian prison.


The two-time Olympic basketball champion and member of the US national team was arrested after being found in possession of a container of cannabis derivative oil.


Before announcing the verdict, Griner told the court that she inadvertently brought an electronic cigarette pod containing cannabis oil with her when she flew to Moscow to play basketball in Yekaterinburg in February.


The legality of possessing marijuana products varies by state and jurisdiction, which may impact the experiences of individuals traveling with such products.


In the United States, marijuana remains illegal under federal law.


Although cannabis is legal for adults in some states in the United States, it is still illegal according to federal law. It is not recommended to transport it across borders.


THC is the primary psychoactive substance in marijuana, while CBD is a non-psychoactive component of cannabis that is typically sold in other products such as lotions and supplements.


Certain cannabis-infused products, including CBD oil, are considered illegal at the federal level if they contain more than 0.3% delta-9-tetrahydrocannabinol (THC) by dry weight.


It is currently unclear whether the ammunition canister carried by Griner, as mentioned by Russian officials, contains either one or both of CBD or THC.


In January 2021, the organization reported that the US Food and Drug Administration has only approved one cannabis-derived product, Epidiolex, which contains purified CBD, as well as three synthetic cannabis-related drug products: Marinol (dronabinol), Syndros (dronabinol), and Cesamet (nabilone). These can only be obtained with a prescription from a licensed healthcare provider.


TSA Does Not Search for Drugs


Officials from the Transport Safety Management Bureau are required to report suspected illegal activities to local, state, or federal authorities, but they will not conduct searches for illegal drugs during screenings.


According to the website, TSA security personnel do not search for marijuana or other illegal drugs, but if any illegal substance is found during the security screening process, the TSA will report it to law enforcement officials.


The TSA has stated that their dogs cannot detect marijuana. However, in an Instagram post, they reiterated that in the screening process, if a substance or product infused with marijuana is found, even for medical use, law enforcement will be notified.


Carrying marijuana products while traveling abroad.


There are no specific guidelines for traveling internationally with cannabis products, but if a certain product is illegal in a particular country or region, carrying it while traveling could have consequences.


For instance, while marijuana is legal for adults in Canada, the government's tourism website states that transporting these products across the Canadian border, regardless of the amount of medical authorization, is illegal.


According to the website, this applies even if the person is traveling to and from a place where marijuana is decriminalized. The consequences of traveling with cannabis products may include being denied entry into a particular country or region.


According to the Canadian government website, "if you have used cannabis or any substance prohibited by local law in the past, you may be denied entry to your destination country." "You may also be refused entry to other countries in the future.


In recent years, Russia has arrested two women for similar reasons.


In Russia, cannabis for recreational or medicinal purposes is illegal.


In April 2019, an Israeli-American woman was arrested at Moscow airport while traveling from India to Israel and found with 9 grams of cannabis in her luggage, according to BBC News.


A 26-year-old woman, Naama Issachar, was sentenced to more than 7 years in prison for drug trafficking. According to the British Broadcasting Corporation, Russian President Vladimir Putin pardoned her in January 2020 before the visit of then-Israeli Prime Minister Benjamin Netanyahu to Moscow.


According to a report by The Moscow Times in September 2019, a film student from New York was charged with possession of drugs in St. Petersburg for allegedly bringing medical marijuana into the country.


2FIRSTS will continue to track and report on this topic, with updates available on the "2FIRSTS APP." Scan the QR code below to download the app.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Trump Picks White House Health Policy Aide Heidi Overton to Lead FDA, Pending Senate Confirmation
Trump Picks White House Health Policy Aide Heidi Overton to Lead FDA, Pending Senate Confirmation
U.S. President Donald Trump has chosen White House health policy aide Heidi Overton to lead the Food and Drug Administration, Bloomberg reported, citing a person familiar with the matter. Overton currently works on health policy at the White House and previously held a senior role at the America First Policy Institute. If confirmed by the Senate, she would take over an FDA that has experienced months of senior-level turnover. The agency regulates products representing roughly one-fifth of U.S. consumer spending, including e-cigarettes, drugs, vaccines and much of the food supply.
News
Aug.19
As FDA Reshapes PMTA Reviews and ENDS Enforcement Priorities, CTP Acting Director Bret Koplow to Keynote NATO Event for a Retail Network of 66,000-Plus Stores
As FDA Reshapes PMTA Reviews and ENDS Enforcement Priorities, CTP Acting Director Bret Koplow to Keynote NATO Event for a Retail Network of 66,000-Plus Stores
Bret Koplow, acting director of the U.S. Food and Drug Administration's Center for Tobacco Products, will deliver a keynote and participate in a fireside chat at the National Association of Tobacco Outlets' Sept. 29-30 conference in Washington. His appearance comes months after the FDA moved to accelerate PMTA reviews and introduced a more differentiated enforcement policy for certain unauthorized ENDS and oral nicotine pouch products. The agency also plans a public list identifying manufacturers and products it does not currently intend to prioritize for enforcement under the May guidance. NATO says its membership includes more than 66,000 retail stores, making product-status transparency and enforcement boundaries directly relevant to the retail sector.
Aug.14
2Firsts Data | China’s Vape Exports Rise 3.1% in H1 2026 as 6-Methyl Nicotine-Related Products Surge 65.2%
2Firsts Data | China’s Vape Exports Rise 3.1% in H1 2026 as 6-Methyl Nicotine-Related Products Surge 65.2%
China’s vape exports showed resilience in the first half of 2026 after a short-term shock from China’s export rebate adjustment. But customs data points to more than a simple recovery: the structure of growth is changing. Vaping devices and atomization hardware emerged as the strongest growth driver, while nicotine-containing vaping products remained broadly stable. Meanwhile, nicotine substitute-related products represented by 6-methyl nicotine expanded rapidly, becoming a new category to watch for both industry and regulators. After the U.S. market went through a cycle of shortages, replenishment and inventory rebuilding in 2025, China’s vape supply chain is entering a new phase of reallocation.
Special Report
Jul.20
Research | Swedish Study Finds Oral Lesions in 79% of Examined Nicotine Pouch Users, With Distinct Tissue Responses
Research | Swedish Study Finds Oral Lesions in 79% of Examined Nicotine Pouch Users, With Distinct Tissue Responses
A new Swedish study found oral mucosal lesions in 79% of examined nicotine pouch users and 89% of tobacco-derived snus users, with different tissue-response patterns between the two categories. For manufacturers and regulators, the findings shift attention toward product formulation, flavouring, pouch materials and local oral exposure, not only whether a product contains tobacco. The study found no higher prevalence of caries or periodontal disease, but it could not establish causality, long-term outcomes or differences between individual products or designs.
Special Report
Jul.27
BAT Regional Director Fred Monteiro Supports Spain’s Nicotine Rules but Opposes 0.99mg Nicotine Pouch Limit
BAT Regional Director Fred Monteiro Supports Spain’s Nicotine Rules but Opposes 0.99mg Nicotine Pouch Limit
Spanish newspaper El Confidencial interviewed Fred Monteiro, Regional Director for Americas and Europe at British American Tobacco (BAT). Monteiro said BAT supports setting regulatory limits for nicotine products but opposes Spain’s proposed 0.99mg nicotine-per-pouch limit, arguing that such a restriction could affect adult smokers’ transition to alternatives. He said nicotine regulation should be based on scientific evidence and harm reduction principles. Monteiro also said smoke-free products now account for around 25% of BAT’s Americas and Europe business and nearly 30% of its Europe business
BAT
Jul.30
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
The U.S. Department of Health and Human Services has named Bret Koplow permanent director of the FDA’s Center for Tobacco Products, ending his period as acting chief. Koplow has spent years working on tobacco regulation, law and policy inside the FDA and, while serving as acting director, pushed for faster PMTA reviews and nicotine pouch review pilots. HHS also said CTP will prioritize innovation and access to less harmful alternatives for adult smokers while continuing efforts to protect youth.
Sep.09